All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Security
Security
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

HHS seeks to ease testosterone therapy restrictions for older men, sparking debate among doctors

By

Allie Yang

2d ago· 7 min readenNews

Summary

The Department of Health and Human Services (HHS) is requesting updates to prescribing information for testosterone replacement therapy (TRT), seeking to roll back restrictions on access for older men that were implemented in 2015 due to concerns about heart risks and limited evidence of benefits. The HHS now argues that newer research supports broader access, but medical experts remain divided — some cite emerging evidence of cardiovascular benefits, while others warn that long-term safety data is still insufficient. The proposal has sparked debate among doctors about whether the evidence justifies loosening restrictions, with concerns about potential overprescription and unknown long-term risks.

Source

Twitter / XHHS seeks to ease testosterone therapy restrictions for older men, sparking debate among doctorstrib.al

Key quotes

· 3 pulled
The department is hoping to roll back restrictions on access for older men — but not all experts are convinced there's enough research to make such sweeping changes.
In 2015, the warnings were added because concerns about heart risks were raised, plus evidence of benefits were 'limited' at the time, the HHS said.
The department said research has come out since then that may support broader access.
Snippet from the RSS feed
The 2015 warnings were added because concerns about heart risks were raised, plus evidence of benefits were “limited” at the time, the HHS said. The department said research has come ou…

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.